Francesco Bifari

Dr. Francesco Bifari

Laboratory of Cell Metabolism and Regenerative Medicine; Department of Medical Biotechnology and Translational Medicine; University of Milan
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2013 in Cell
Verified
Journal Article
Closed access
KBKatrien De Bock
Katrien De Bock
MGMaria Georgiadou
Maria Georgiadou
SSSandra Schoors
Sandra Schoors
AKAnna Kuchnio
Anna Kuchnio
BWBrian W. Wong
Brian W. Wong
PCPeter Carmeliet
Peter Carmeliet

1 December 2016 in Cancer Cell
Verified
Journal Article
Closed access
Anna Rita CantelmoAnna Rita Cantelmo
Anna Rita Cantelmo
LCLena-Christin Conradi
Lena-Christin Conradi
ABAleksandra Brajic
Aleksandra Brajic
JGJermaine Goveia
Jermaine Goveia
JKJoanna Kalucka
Joanna Kalucka
PCPeter Carmeliet
Peter Carmeliet

1 January 2014 in Cell Metabolism
Verified
Journal Article
Closed access
SSSandra Schoors
Sandra Schoors
KBKatrien De Bock
Katrien De Bock
Anna Rita CantelmoAnna Rita Cantelmo
Anna Rita Cantelmo
MGMaria Georgiadou
Maria Georgiadou
Bart GhesquiereBart Ghesquiere
Bart Ghesquiere
PCPeter Carmeliet
Peter Carmeliet

12 August 2009 in Stem Cells
Verified
Journal Article
Open access
PDF file
GCGabriela Constantin
Gabriela Constantin
SMSilvia Marconi
Silvia Marconi
BRBarbara Rossi
Barbara Rossi
SAStefano Angiari
Stefano Angiari
Laura CalderanLaura Calderan
Laura Calderan
Bruno BonettiBruno Bonetti
Bruno Bonetti
Mesenchymal stem cells (MSCs) represent a promising therapeutic approach for neurological autoimmune diseases; previous studies have shown that treatment with bone marrow-derived MSCs induces immune modulation and reduces disease severity in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis. Here we show that intravenous administration of adipose-derived MSCs (ASCs) before disease onset significantly reduces the severity of EAE by immune modulation and decreases spinal cord inflammation and demyelination. ASCs preferentially home into lymphoid organs but also migrates inside the central nervous system (CNS). Most importantly, administration of ASCs in chronic established EAE significantly ameliorates the disease course and reduces both demyelination and axonal loss, and induces a Th2-type cytokine shift in T cells. Interestingly, a relevant subset of ASCs expresses activated α4 integrins and adheres to inflamed brain venules in intravital microscopy experiments. Bioluminescence imaging shows that α4 integrins control ASC accumulation in inflamed CNS. Importantly, we found that ASC cultures produce basic fibroblast growth factor, brain-derived growth factor, and platelet-derived growth factor-AB. Moreover, ASC infiltration within demyelinated areas is accompanied by increased number of endogenous oligodendrocyte progenitors. In conclusion, we show that ASCs have clear therapeutic potential by a bimodal mechanism, by suppressing the autoimmune response in early phases of disease as well as by inducing local neuroregeneration by endogenous progenitors in animals with established disease. Overall, our data suggest that ASCs represent a valuable tool for stem cell–based therapy in chronic inflammatory diseases of the CNS.

8 February 2016 in The EMBO Journal
Verified
Journal Article
Closed access
PDF file
CLChristian Lange
Christian Lange
MGMiguel Turrero Garcia
Miguel Turrero Garcia
IDIlaria Decimo
Ilaria Decimo
Francesco BifariFrancesco Bifari
Francesco Bifari
GEGuy Eelen
Guy Eelen
PCPeter Carmeliet
Peter Carmeliet

15 June 2013 in Stem Cells and Development
Verified
Journal Article
Closed access
CMCedric Menard
Cedric Menard
LPLuciano Pacelli
Luciano Pacelli
GBGiulio Bassi
Giulio Bassi
JDJoelle Dulong
Joelle Dulong
Francesco BifariFrancesco Bifari
Francesco Bifari
MKMauro Krampera
Mauro Krampera
Clinical-grade mesenchymal stromal cells (MSCs) are usually expanded from bone marrow (BMMSCs) or adipose tissue (ADSCs) using processes mainly differing in the use of fetal calf serum (FCS) or human platelet lysate (PL). We aimed to compare immune modulatory properties of clinical-grade MSCs using a combination of fully standardized in vitro assays. BMMSCs expanded with FCS (BMMSC-FCS) or PL (BMMSC-PL), and ADSC-PL were analyzed in quantitative phenotypic and functional experiments, including their capacity to inhibit the proliferation of T, B, and NK cells. The molecular mechanisms supporting T-cell inhibition were investigated. These parameters were also evaluated after pre-stimulation of MSCs with inflammatory cytokines. BMMSC-FCS, BMMSC-PL, and ADSC-PL displayed significant differences in expression of immunosuppressive and adhesion molecules. Standardized functional assays revealed that resting MSCs inhibited proliferation of T and NK cells, but not B cells. ADSC-PL were the most potent in inhibiting T-cell growth, a property ascribed to interferon-γ-dependent indoleamine 2,3-dioxygenase activity. MSCs did not stimulate allogeneic T cell proliferation but were efficiently lysed by activated NK cells. The systematic use of quantitative and reproducible validation techniques highlights differences in immunological properties of MSCs produced using various clinical-grade processes. ADSC-PL emerge as a promising candidate for future clinical trials.